178 related articles for article (PubMed ID: 22585092)
1. Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly.
Lekva T; Berg JP; Fougner SL; Olstad OK; Ueland T; Bollerslev J
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1506-14. PubMed ID: 22585092
[TBL] [Abstract][Full Text] [Related]
2. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
[TBL] [Abstract][Full Text] [Related]
3. Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery.
Lekva T; Berg JP; Heck A; Lyngvi Fougner S; Olstad OK; Ringstad G; Bollerslev J; Ueland T
PLoS One; 2013; 8(6):e66927. PubMed ID: 23825587
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing of placental lactogen (CSH2) in somatotroph pituitary adenomas.
Lekva T; Berg JP; Lyle R; Heck A; Bollerslev J; Ueland T
Neuro Endocrinol Lett; 2015; 36(2):136-42. PubMed ID: 26071582
[TBL] [Abstract][Full Text] [Related]
5. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response.
Fougner SL; Lekva T; Borota OC; Hald JK; Bollerslev J; Berg JP
J Clin Endocrinol Metab; 2010 May; 95(5):2334-42. PubMed ID: 20335450
[TBL] [Abstract][Full Text] [Related]
6. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
7. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
[TBL] [Abstract][Full Text] [Related]
8. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.
Zhou C; Jiao Y; Wang R; Ren SG; Wawrowsky K; Melmed S
J Clin Invest; 2015 Apr; 125(4):1692-702. PubMed ID: 25774503
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly.
Gil J; Jordà M; Soldevila B; Puig-Domingo M
Front Endocrinol (Lausanne); 2021; 12():646210. PubMed ID: 33790868
[TBL] [Abstract][Full Text] [Related]
10. Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas.
Chauvet N; Romanò N; Meunier AC; Galibert E; Fontanaud P; Mathieu MN; Osterstock G; Osterstock P; Baccino E; Rigau V; Loiseau H; Bouillot-Eimer S; Barlier A; Mollard P; Coutry N
J Neuroendocrinol; 2016 Feb; 28(2):12352. PubMed ID: 26686489
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal Transition (EMT) Markers in Human Pituitary Adenomas Indicate a Clinical Course.
Jia W; Zhu J; Martin TA; Jiang A; Sanders AJ; Jiang WG
Anticancer Res; 2015 May; 35(5):2635-43. PubMed ID: 25964539
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of microRNAs in GH-secreting pituitary adenomas.
Mao ZG; He DS; Zhou J; Yao B; Xiao WW; Chen CH; Zhu YH; Wang HJ
Diagn Pathol; 2010 Dec; 5():79. PubMed ID: 21138567
[TBL] [Abstract][Full Text] [Related]
13. CCNB1 affects cavernous sinus invasion in pituitary adenomas through the epithelial-mesenchymal transition.
Li B; Cheng J; Wang H; Zhao S; Zhu H; Li C; Zhang Y; Zhao P
J Transl Med; 2019 Oct; 17(1):336. PubMed ID: 31585531
[TBL] [Abstract][Full Text] [Related]
14. Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation.
Xu T; Ye F; Wang B; Tian C; Wang S; Shu K; Guo D; Lei T
Neuro Endocrinol Lett; 2010; 31(1):147-54. PubMed ID: 20150876
[TBL] [Abstract][Full Text] [Related]
15. Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly.
Mendes GA; Haag T; Trott G; Rech CGSL; Ferreira NP; Oliveira MC; Kohek MB; Pereira-Lima JFS
Braz J Med Biol Res; 2017 Dec; 51(2):e6808. PubMed ID: 29267504
[TBL] [Abstract][Full Text] [Related]
16. The aging suppressor klotho: a potential regulator of growth hormone secretion.
Shahmoon S; Rubinfeld H; Wolf I; Cohen ZR; Hadani M; Shimon I; Rubinek T
Am J Physiol Endocrinol Metab; 2014 Aug; 307(3):E326-34. PubMed ID: 24939736
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
Chahal HS; Trivellin G; Leontiou CA; Alband N; Fowkes RC; Tahir A; Igreja SC; Chapple JP; Jordan S; Lupp A; Schulz S; Ansorge O; Karavitaki N; Carlsen E; Wass JA; Grossman AB; Korbonits M
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1411-20. PubMed ID: 22659247
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.
Obari A; Sano T; Ohyama K; Kudo E; Qian ZR; Yoneda A; Rayhan N; Mustafizur Rahman M; Yamada S
Endocr Pathol; 2008; 19(2):82-91. PubMed ID: 18629656
[TBL] [Abstract][Full Text] [Related]
19. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly.
Fougner SL; Casar-Borota O; Heck A; Berg JP; Bollerslev J
Clin Endocrinol (Oxf); 2012 Jan; 76(1):96-102. PubMed ID: 21722151
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of sex-determining region Y-box 9 (SOX9) in growth hormone-secreting pituitary adenomas.
Shirian FI; Ghorbani M; Khamseh ME; Imani M; Panahi M; Alimohammadi A; Nourbakhsh M; Salimi V; Tavakoli-Yaraki M
BMC Endocr Disord; 2021 Mar; 21(1):50. PubMed ID: 33736633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
